Patent Grant
11655497
Human genetic mutations whether it is de novo or somatic are critical information to understand human genetic disease (Ku, C. S. et al, A new era in the discovery of de novo mutations underlying human genetic disease, Hum Genomics 6, 27, 2012), cancer biology (Helleday, T. et al, Mechanisms underlying mutational signatures in human cancers, Nat Rev Genet 15, 585-598, 2014) and potential anticancer therapies. de novo mutation has long been known to cause genetic disease and it also plays an important role in rare and common forms of neurodevelopmental diseases, including intellectual disability, autism and schizophrenia (Veltman, J. A. et al, De novo mutations in human genetic disease, Nat Rev Genet 13, 565-575, 2012). Somatic mutation in cancer genome has been extensively studied and believed to hold the key to understand cancer origin, risk and potential biomarker discovery for therapeutic use. Detection of those genetic mutations is critical for diagnosis of disease and patient treatment.
Studies of de novo or somatic mutations in the human genome have been very challenging in the past because of genomic sequencing technology limitations. However, the development of high-throughput next-generation sequencing (NGS) technologies has greatly facilitated the study of such mutations. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) can now be performed on parent offspring trios to identify de novo point mutations in the entire genome or within protein-coding regions, respectively.
WGS and WES are great tools for genetic mutation study, but they are still cost prohibitive for routine clinical use. In some cases, if only a set of genetic mutations are known to be related with certain disease or particular drug response, it would be efficient and cost effective to do genetic analysis for those genes. In order to do a limited resequencing of panel of genes, those genes need to be captured before carrying out NGS. The capture process could be achieved using either hybridization or amplicon approach. For hybridization capture approach, gDNA was first physically fragmented or enzymatically digested, then synthetic oligonucleotides are hybridized to regions of interest in solution to capture the intended sequences. For amplicon based approach, the intended regions are directly captured by amplification of PCR primers. Hybridization capture approach is scalable to large number of genes, but hybridization step usually takes overnight and the total process takes multiple days. It also requires at least 1 to 2 μg of gDNA material input. Amplicon based approach takes less time and only require 10 to 50 ng gDNA input, so it is suitable if quantities of DNA input from clinical samples are limited. However, multiplex PCR primers also generate nonspecific amplification products especially when the number of PCR primers increase. In fact, majority of PCR products are nonspecific amplicons when the number of primers approaches hundreds. Therefore, amplicon based approach usually uses an enzyme digestion step to reduce nonspecific amplification product followed by additional ligation step or use a multiple steps of cleaning up to reduce those nonspecific products. Those nonspecific amplification products not only require multiple steps during sequencing library generation but also can introduce sequencing data errors.
Recently detection of low frequency mutation has been a rapidly growing area of interest because of its important applications in basic and clinical research. One kind of rare mutations, circulating cell-free DNA (cfDNA) from human plasma are used for prenatal screening (Chiu, R. W. et al, Noninvasive prenatal diagnosis empowered by high-throughput sequencing, Prenat Diagn 32, 401-406, 2012), while circulating tumor DNA (ctDNA) has been confirmed to contain the hallmark mutations of cancerous cells. ctDNA has the potential to be a novel, non-invasive biomarker that promotes early cancer detection at a surgically curable stage, reduces the necessity of repeat tissue biopsies, and detects the early relapse of the disease, thereby increasing the efficacy of targeted therapy. For cancers that are often detected at a late stage, including lung, pancreatic, and ovarian etc., a high-sensitivity ctDNA assay could be used as an important screening test to detect typically terminal metastatic stage cancer at an earlier, potentially curable stage. With continuous ctDNA monitoring from patient blood, change of ctDNA composition and quantitation could be used to monitor cancer progression in real time, improving patient safety and eliminating the cost related to repeat tissue biopsies.
Unfortunately, detection of ctDNA remains challenging by its presence in relatively low quantities especially in early-stage cancer patients. There are several available techniques developed so far to detect ctDNA including BEAMing, digital PCR, and next generation sequencing. All those methods can detect low frequency mutations by assessing individual molecules one-by-one. NGS has the advantage over traditional methods in that large amount of sequencing information can be obtained easily in an automated fashion. However, NGS cannot generally be used to detect rare mutations because of its high error rate associated with NGS library generation and the sequencing process. Some of these errors presumably result from mutations introduced during template preparation, during the pre-amplification steps required for library preparation and during further solid-phase amplification on the instrument itself. Other errors are due to base mis-incorporation during sequencing and base-calling errors.
Therefore, there remains a continuing need for a novel approach to eliminate nonspecific amplification products during multiplex PCR reaction so that the sequencing library could be directly generated without additional digestion and ligation steps, and a novel approach to reduce error rate so that rare mutation could be reliably detected using current NGS instrument.
One aspect of the present disclosure provides a method of amplifying a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample comprising or suspected of comprising the target nucleic acid, (ii) at least 20 different types of primer pairs, wherein at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid, and each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primers; and (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid.
In some embodiments, the blocking group is at or near 3′ terminal of each blocking primer. In some embodiments, the blocking group is 2′, 3′-dideoxynucleotide, ribonucleotide residue, 2′, 3′SH nucleotide, or 2′-O—PO3 nucleotide.
In some embodiments, the blocking primer is complementary to a portion of the target nucleic acid. In some embodiments, the blocking primer is further modified to decrease the amplification of undesired nucleic acid. In some embodiments, the modification is introduction of at least one mismatched nucleotide in the primer. In some embodiments, the mismatched nucleotide is 2-18 bp away from the nucleotide with the blocking group. In some embodiments, wherein the mismatched nucleotide is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 bp away from the nucleotide with the blocking group. In some embodiments, the mismatched nucleotide base is located on the 5′ side of the nucleotide with the blocking group. In some embodiments, the modification is a modification to decrease the Tm between the blocking primer and the undesired nucleic acid. In some embodiments, the modification is a modification to increase the Tm between the blocking primer and the target nucleic acid. In some embodiments, wherein the modification is a modification to form an extra bridge connecting the 2′ oxygen and 4′ carbon of at least one nucleotide of the blocking primer.
In some embodiments, there are no more than 20 complementary nucleotide pairings and no more than 50% sequence complementarity between any two primers. In some embodiments, there are no more than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 complementary nucleotide pairings between any two primers.
In some embodiments, the reaction mixture comprises at least 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 400, 500, 600, 700, 800, 900 or 1000 different types of primer pairs.
In some embodiments, each of the primers is 8 to 100 nucleotides in length.
In some embodiments, the different types of primer pairs can complementarily bind to different target nucleic acids or different sequences in the same target nucleic acid.
In some embodiments, wherein the de-blocking agent is CS5 DNA polymerase with the mutations selected from G46E, L329A, Q601R, D640G, I669F, S671F, E678G or the combination of such mutations, ampliTaq or KlenTaq polymerase with F667Y mutation, pyrophosphate or RNase H2.
In some embodiments, the target nucleic acid is single stranded or double stranded DNA.
In some embodiments, the target nucleic acid is double stranded DNA ligated with single or double adaptor tags or single stranded DNA ligated with single adaptor tag.
In some embodiments, the reaction mixture further comprises at least one primer complementary in whole or in part with the adaptor tag.
In some embodiments, the target nucleic acid is double stranded DNA comprising single or double molecular index tag or single stranded DNA comprising single molecular index tag. In some embodiments, the molecular index tag comprises unique identifier nucleic acid sequence and an adaptor tag.
In some embodiments, the primers have common tailing sequence at or near 5′ terminal of the primers. In some embodiments, the common tailing sequence can be used as molecular index tag, sample index tag or adaptor tag or combinations of all three tags.
In some embodiments, the reaction mixture further comprises high fidelity polymerase. In some embodiments, the high fidelity polymerase is PFU DNA Polymerase.
In some embodiments, the step (b) “incubating the reaction mixture under a condition for amplification of the target nucleic acid” comprises the steps of denaturing the target nucleic acid; annealing the primers with the target nucleic acid to allow the formation of a nucleic acid-primer hybrid; and incubating the nucleic acid-primer hybrid to allow the nucleic acid polymerase to amplify the target nucleic acid.
In some embodiments, the formation of a nucleic acid-primer hybrid results in de-blocking the block group in the primer through de-blocking agent.
In some embodiments, the steps of “denaturing the target nucleic acid; annealing the primers with the target nucleic acid to allow the formation of a nucleic acid-primer hybrid; and incubating the nucleic acid-primer hybrid to allow the nucleic acid polymerase to amplify the target nucleic acid” is repeated at least 1 time, 5 times, 10 times, 15 times, 20 times, 25 times, 30 times, 35 times, 40 times or 50 times. In some embodiments, the step (b) is repeated from about 20 times to about 50 times.
In some embodiments, the nucleic acid sample comprises the target nucleic acid. In some embodiments, the target nucleic acids in the nucleic acid sample is no more than 1 copy, 2 copies, 5 copies, 8 copies, 10 copies, 20 copies, 30 copies, 50 copies, 80 copies or 100 copies. In some embodiments, the molar percentage of target nucleic acid in the nucleic acid sample is less than 50%, 20%, 10%, 5%, 3%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.005%, or 0.001%.
In some embodiments, the nucleic acid other than the target nucleic acid is not amplified in step (b) substantially. In some embodiments, the molar percentage of undesired nucleic acid in the reaction products obtained from step (b) is less than 20%, 15%, 10%, 5%, 3%, 2% or 1%.
In some embodiments, the method is used for selective enrichment of mutant nucleic acid in a sample comprising wildtype nucleic acid. In some embodiments, wherein at least one blocking primer is complementary to the mutant nucleic acid at the mutant residues and the nucleotide of the blocking primer corresponding to a mutant residue has the blocking group.
Another aspect of the present disclosure provides a method of sequencing a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample comprising or suspected of comprising the target nucleic acid, (ii) at least 20 different types of primer pairs, wherein at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid, and each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primers; (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid; and (c) determining the sequence of the reaction products obtained from step (b).
In some embodiments, the method is used for sequencing by capillary electrophoresis, PCR or high throughput sequencing. In some embodiments, the blocking primer is further modified to decrease the amplification of undesired nucleic acid.
In some embodiments, the reaction mixture further comprises high fidelity polymerase.
Yet another aspect of the present disclosure provides a method of sequencing a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample comprising or suspected of comprising the target nucleic acid, (ii) at least 20 different types of primer pairs, wherein at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid, and each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primers; (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid; (c) adding adaptor tag, molecular index tag and/or sample index tag to the reaction products obtained from step (b); and (d) determining the sequence of the reaction products obtained from step (c).
In some embodiments, the method is used for sequencing by capillary electrophoresis, PCR or high throughput sequencing.
In some embodiments, wherein the blocking primer is modified to decrease the amplification of undesired nucleic acid.
In some embodiments, wherein the reaction mixture further comprises high fidelity polymerase.
Yet another aspect of the present disclosure provides a kit for amplifying a target nucleic acid, wherein the kit comprises: (i) at least 20 different types of primer pairs, wherein at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid, and each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, (ii) nucleic acid polymerase, and (iii) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primer.
In some embodiments, the blocking primer is modified to decrease the amplification of undesired nucleic acid.
In some embodiments, the reaction mixture further comprises high fidelity polymerase.
Yet another aspect of the present disclosure provides a method of amplifying a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample comprising or suspected of comprising the target nucleic acid, (ii) at least one type of primers that is complementary to a portion of the target nucleic acid, and each type of primers has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, wherein the blocking primer is modified to decrease the amplification of undesired nucleic acid, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primer; and (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid.
In some embodiments, the modification is introduction of at least one mismatched nucleotide in the primer.
In some embodiments, the mismatched nucleotide is 2-18 bp away from the nucleotide with the blocking group.
In some embodiments, the mismatched nucleotide is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 bp away from the nucleotide with blocking group.
In some embodiments, the mismatched nucleotide is located on the 5′ side of the blocking group.
In some embodiments, the modification is a modification to decrease the affinity between the blocking primer and the target nucleic acid.
In some embodiments, the modification is a modification to form an extra bridge connecting the 2′ oxygen and 4′ carbon of at least one nucleotide of the blocking primer.
In some embodiments, the method is used for selective enrichment of mutant nucleic acid in a sample comprising wild type nucleic acid.
In some embodiments, a blocking primer is complementary to a portion of the target nucleic acid. In some embodiments, the blocking primer is complementary to the mutant nucleic acid at the mutant residue and the nucleotide of the blocking primer corresponding to a mutant residue has the blocking group.
Yet another aspect of the present disclosure provides a kit for amplifying a target nucleic acid, wherein the kit comprises: (i) at least one type of primers that is complementary to a portion of the target nucleic acid, and each type of primers have at least one blocking primer comprising a blocking group capable of blocking polymerase extension, wherein the blocking primer is modified to decrease the amplification of undesired nucleic acid, (ii) nucleic acid polymerase, and (iii) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primer.
In some embodiments, the blocking primer is modified to decrease the affinity between the blocking primer and the target nucleic acid.
One aspect of the present disclosure provides a method of amplifying a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture; and (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid.
Providing a Reaction Mixture
In some embodiments, a reaction mixture for detecting a target nucleic acid of the present disclosure comprises: (i) a nucleic acid sample comprising or suspected of comprising the target nucleic acid, (ii) at least 20 different types of primer pairs, wherein at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid, and each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase using the blocking primers.
Nucleic Acid Sample
The term “nucleic acid” as used in the present disclosure refers to a biological polymer of nucleotide bases, and may include but is not limited to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (miRNA), and peptide nucleic acid (PNA), modified oligonucleotides (e.g., oligonucleotides comprising nucleotides that are not conventional to biological RNA or DNA, such as 2′-O-methylated oligonucleotides), and the like. The nucleotides of the present disclosure can be natural or unnatural, substituted or unsubstituted, modified or unmodified. The nucleotides can be linked by phosphodiester bonds, or by phosphorothioate linkages, methylphosphonate linkages, boranophosphate linkages, or the like. The polynucleotides can additionally comprise non-nucleotide elements such as labels, quenchers, blocking groups, or the like. The nucleic acid can be, e.g., single-stranded or double-stranded.
The term “DNA” as used in the present disclosure refers to deoxyribonucleic acid, a long chain polymer biological macromolecule which forms genetic instructions. The subunit of DNA is nucleotide. Each nucleotide in DNA consists of a nitrogenous base, a five-carbon sugar (2-deoxyribose) and phosphate groups. Neighboring nucleotides are linked via diester bonds formed by deoxyribose and phosphoric acid, thereby forming a long chain framework. Generally, there are four types of nitrogenous bases in DNA nucleotides, namely adenine (A), guanine (G), and cytosine (C), thymine (T). The bases on the two DNA long chains pair via hydrogen bonds, wherein adenine (A) pairs with thymine (T), and guanine (G) pairs with cytosine (C).
The term “nucleic acid sample” as used in the present disclosure refers to any sample containing nucleic acid, including but not limited to cells, tissues, and body fluids, etc. In some embodiments, the nucleic acid sample is a tissue, e.g., biopsy tissue or paraffin embedded tissue. In some embodiments, the nucleic acid sample is bacteria or animal or plant cells. In some other embodiments, the nucleic acid sample is a body fluid, e.g., blood, plasma, serum, saliva, amniocentesis fluid, pleural effusion, seroperitoneum, etc. In some embodiments, the nucleic acid sample is blood, serum or plasma.
In some embodiments, the nucleic acid sample comprises or is suspected of comprising the target nucleic acid.
The term “target nucleic acid” or “target region” as used in the present disclosure refers to any region or sequence of a nucleic acid which is to be amplified intentionally.
In some specific embodiments, the target nucleic acid is DNA, RNA or a hybrid or a mixture thereof. In some specific embodiments, the target nucleic acid is genomic DNA. In some specific embodiments, the target nucleic acid is cell-free DNA (cfDNA). In some specific embodiments, the target nucleic acid is circulating tumor DNA (ctDNA).
“Cell-free DNA” as used in the present disclosure refers to DNA released from cells and found in circulatory system (e.g., blood), the source of which is generally believed to be genomic DNA released during apoptosis.
“Circulating tumor DNA” as used in the present disclosure refers to the cell-free DNA originated from tumor cells. In human body, a tumor cell may release its genomic DNA into the blood due to causes such as apoptosis and immune responses. Since a normal cell may also release its genomic DNA into the blood, circulating tumor DNA usually constitutes only a very small part of cell-free DNA.
In some embodiments, the target nucleic acid is single stranded or double stranded DNA. In some embodiments, the target nucleic acid is the whole or a portion of one or more genes selected from ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53 and VHL.
In some embodiments, the amount of target nucleic acid in the nucleic acid sample is no more than 1 copy, 2 copies, 3 copy, 4 copies, 5 copies, 6 copies, 7 copies, 8 copies, 9 copies, 10 copies, 12 copies, 15 copies, 18 copies, 20 copies, 30 copies, 50 copies, 80 copies or 100 copies. In some embodiments, the molar percentage (molar/molar) of target nucleic acid in the nucleic acid sample is less than 50%, 20%, 10%, 8%, 6%, 5%, 3%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.005%, or 0.001%. In some embodiments, the ratio of molar of target nucleic acid and the molar of un-target nucleic acid in the nucleic acid sample is less than 50%, 20%, 10%, 8%, 6%, 5%, 3%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, 0.005%, or 0.001%.
In some embodiments, the target nucleic acid is DNA fragment. In some embodiments, the size of the target nucleic acid is 0.01-5 kb, 0.1-5 kb, 0.1-1 kb, 1-2 kb, 2-3 kb, 3-4 kb, 4-5 kb, 0.2-0.4 kb, 0.5-1 kb, 0.1-0.5 kb, 0.01-0.5 kb, 0.01-0.4 kb, 0.01-0.3 kb, 0.01-0.25 kb, 0.02-0.25 kb, 0.05-0.3 kb or 0.05-0.25 kb. The DNA fragment can be obtained through common technology in the art (e.g., physical breaking, cleavage using specific restriction endonuclease, etc.).
In some embodiments, the target nucleic acid is double stranded DNA ligated with single or double adaptor tags or single stranded DNA ligated with single adaptor tag.
The term “adaptor tag” as used in the present disclosure refers to a specific DNA sequence attached to one or two ends of a nucleic acid (single stranded or double stranded) according to needs, and the length of the adaptor is usually within 5-50 bp. The adaptor tag can be used to facilitate amplifying the target nucleic acid and/or sequencing the amplified target nucleic acid. In some embodiments, the adaptor tag is used to facilitate the ligation of tags for sequencing (e.g., the ligation of P5 and P7 tag for Illumina MiSeq sequencer). In some embodiments, the adaptor tag is attached to only one end of a single stranded nucleic acid at 3′ terminal or 5′ terminal. In some embodiments, the adaptor tag is attached to two ends of a single stranded nucleic acid. In some embodiments, one adaptor tag is attached to each strand in double stranded nucleic acid at 3′ terminal or 5′ terminal. For example, one adaptor tag is attached to one strand in double stranded nucleic acid at its 3′ terminal and one adaptor tag is attached to the other strand in double stranded nucleic acid at its 5′ terminal, and the two adaptor tags are identical or complementary to each other. In some embodiments, two adaptor tags are attached to two ends of each strand in double stranded nucleic acid.
The adaptor tag can be attached to the nucleic acid through common technologies in the art. In some embodiments, where the target nucleic acid is double stranded DNA, the adaptor tag can be attached to the nucleic acid through the following steps: (a) providing an adaptor ligation nucleic acid designed to contain sequences to ligate with an end of one strand of the DNA (for example, the adaptor ligation nucleic acid contains a hybridization complementary region, or a random hybridization short sequence, e.g., poly-T); (b) hybridization of the adaptor ligation nucleic acid and the strand of the DNA; and (c) adding polymerase (e.g., reverse transcriptase) after the hybridization to extend the adaptor ligation nucleic acid, thereby the adaptor tag is ligated to the end of the target DNA fragment. For attaching another adaptor to the other end of the same strand or to the other strand of the DNA, an adaptor ligation nucleic acid can be designed according to the needs and steps (b)-(c) can be repeated. In some other embodiments, where the DNA fragment is double stranded and the end of the DNA fragment is a sticky end, the adaptor tag can be attached to the nucleic acid through the following steps: (a) designing the adaptor ligation nucleic acid to contain sequences to ligate with the sticky end; (b) complementarily annealing the adaptor ligation nucleic acid with the sticky end; and (c) ligating the adaptor ligation nucleic acid to the double stranded of the target DNA using a ligase, thereby achieving the purpose of attaching the adapter to the end of the DNA fragment.
In some embodiments, the target nucleic acid is double stranded DNA comprising single or double molecular index tags or single stranded DNA comprising single molecular index tag. In some embodiments, the molecular index tag comprises unique identifier nucleic acid sequence and an adaptor tag. In some embodiments, the adaptor tag is at one end of the target nucleic acid.
The term “molecular index tag” as used in the present disclosure refers to a nucleic acid sequence used as a tag, which can be ligated to or existing at the 5′ end, the 3′ end or both ends of a DNA fragment. In DNA sequencing, especially in high throughout sequencing technology, a molecular index tag therein is used to mark particular DNA molecule. After amplification and sequencing, the count of the molecular index sequence therein is used to mark particular DNA molecule and can be the basis for determining the quantity of expression of the marked gene, or be used to trace the information of the amplified DNA molecules from the same original molecules and thereby correcting the random errors of DNA sequences during amplification and sequencing.
In some embodiments, the molecular index tag is exogenous, which is attached to the target nucleic acid through PCR (e.g., as described in MoCloskey M. L. et al, Encoding PCR products with batch-stamps and barcodes. Biochem Genet 45:761-767, 2014 or Parameswaran P, et al., A pyrosequencing-tailored nucleotide barcode design unveils opportunities for large-scale sample multiplexing. Nucleic Acids Res 35:e130, 2017) or ligation (e.g., as described in Craig D W, et al., Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods 5:887-893, 2008 or Miner B E, et al., Molecular barcodes detect redundancy and contamination in hairpin-bisulfite PCR. Nucleic Acids Res 32:e135, 2004). In some embodiments, the molecular index tag or the unique identifier nucleic acid sequence therein can be a random sequence (i.e., formed with randomly arranged A/T/C/G).
In some embodiments, the molecular index tag or the unique identifier nucleic acid sequence therein is endogenous, which are the sequences of the two ends of randomly sheared fragment.
More information for molecular index tag can be found in U.S. 20140227705 and U.S. 20150044687.
Primer
The term “primer” as used in the present disclosure refers to an oligonucleotide that is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. Primer may comprise natural ribonucleic acid, deoxyribonucleic acid, or other forms of natural nucleic acid. Primer may also comprise un-natural nucleic acid (e.g., LNA, ZNA etc.).
Primers may be prepared using any suitable method, such as, for example, the phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethylophosphoramidites are used as starting materials and may be synthesized as described by Beaucage et al., Tetrahedron Letters, 22:1859-1862 (1981). One method for synthesizing primer on a modified solid support is described in U.S. Pat. No. 4,458,006. It is also possible to use a primer which has been isolated from a biological source, such as a restriction endonuclease digest. In some embodiments, the primer with blocking nucleotide at the 3′ end, can be synthesized with terminal transferase (Gibco BRL) (Nuc Aci Res 2002, 30(2)).
The term “primer pair” as used in the present disclosure refers to a pair of primers consisting of a forward primer and a reverse primer which complement with a portion of a sequence to be amplified, respectively, wherein the forward primer defines a point of initiation of the amplified sequence and the reverse primer defines a point of termination of the amplified sequence. The term “complimentary”, when it is used to describe the relationship between primer and the sequence to be amplified, refers to that the primer is complimentary to the sequence to be amplified or is complimentary to a complementary sequence of the sequence to be amplified.
The pair of primers can be designed based on the sequence of the target nucleic acid. In some embodiments, at least one primer of each type of primer pairs is complementary to a portion of the target nucleic acid. In some embodiments, when the target sequence (assuming it is a double stranded DNA) has an adaptor tag, one primer of a primer pair may be complementary to a portion of the target sequence (on one strand) and the other primer may be complementary to the adaptor tag (on the other strand).
In some embodiments, each primer pair has at least one blocking primer comprising a blocking group capable of blocking polymerase extension. In some embodiments, both primers in each primer pair are blocking primers comprising a blocking group capable of blocking polymerase extension.
The term “blocking primer” as used in the present disclosure refers to a primer having a blocking group.
The term “blocking group” as used in the present disclosure refers to any chemical group covalently linked in a nucleic acid chain and capable of blocking polymerase extension. In some embodiments, the nucleotide with blocking group is a modified nucleotide at or near the 3′ terminal of each blocking primer. In some embodiments, the nucleotide with blocking group is no more than 6 bp, 5 bp, 4 bp, 3 bp, 2 bp or 1 bp away from the 3′ terminal of each blocking primer. In some embodiments, when the method of the present disclosure is used for selective enrichment of mutant nucleic acid in a sample comprising wildtype nucleic acid, the blocking group is at the nucleotide that is complementary with the corresponding mutated nucleotide of the mutant nucleic acid but is not complementary with the corresponding nucleotide of wildtype nucleic acid.
In some embodiments, the blocking group is 2′, 3′-dideoxynucleotide, ribonucleotide residue, 2′, 3′SH nucleotide, or 2′-O—PO3 nucleotide. When the blocking group is a ribonucleotide residue, the blocking primer is a primer that has one ribonucleotide residue and other residues are all deoxyribonucleotide residues.
More information for blocking group and blocking primer can be found in U.S. Pat. Nos. 9,133,491, 6,534,269 and Joseph R. D. et al., RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers, BMC Biotechnology 11:80, 2011.
In some embodiments, the blocking primer is complementary to a portion of the target nucleic acid.
In some embodiments, the primers are 5 to 100 nucleotides in length. In some embodiments, the primers are at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 or 40 nucleotides in length. In some embodiments, the primers are no more than 100, 90, 80, 70, 60, 50, 40, 35, 30, 25 or 20 nucleotides in length.
In some embodiments, a primer comprises a complementary region that is complementary to the target sequence and a common tailing sequence at or near the 5′ terminal of the primer. In some embodiments, the common tailing sequence can be used as molecular index tag, adaptor tag or sample index tag or combinations of all the three tags.
The term “sample index tag” as used in the present disclosure refers to a series of unique nucleotides (i.e., each sample index tag is unique), and can be used to allow for multiplexing of samples such that each sample can be identified based on its sample index tag. In some embodiments, there is a unique sample index tag for each sample in a set of samples, and the samples are pooled during sequencing. For example, if twelve samples are pooled into a single sequencing reaction, there are at least twelve unique sample index tags such that each sample is labeled uniquely.
In some embodiments, the blocking primer is modified so as to further decrease the amplification of undesired nucleic acid.
In some embodiments, the modification is introduction of at least one mismatched nucleotide in the primer. In some embodiments, the mismatched nucleotide base is located on the 5′ side of the nucleotide with the blocking group.
The term “mismatched nucleotide” as used in the present disclosure refers to a nucleotide of a first nucleic acid (e.g., primer) that is not capable of pairing with a nucleotide at a corresponding position of a second nucleic acid (e.g., target nucleic acid), when the first and second nucleic acids are aligned.
The preferred or accepted location of the mismatched nucleotide can be determined through conventional technologies. For example, the mismatched nucleotides are introduced into different locations in the blocking primer, and those blocking primers are used for amplifying a target nucleic acid separately, and then the preferred or accepted location of the mismatched nucleotide for the target nucleic acid can be determined based on the results of amplification (e.g., the location decreasing the amplification of undesired nucleic acid or false positive results is preferred or accepted location). The location of the mismatched nucleotide may change along with the change of the target nucleic acid or the structure of the blocking primer. In some embodiments, the mismatched nucleotide is 2-18 bp away from the nucleotide with blocking group. In some embodiments, the mismatched nucleotide is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 bp away from the nucleotide with blocking group. In some embodiments, the mismatched nucleotide is no less than 2, 3, 4, 5, 6, 7, 8, 9 or 10 bp away from the nucleotide with blocking group. In some embodiments, the mismatched nucleotide is no more than 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2 bp away from the nucleotide with blocking group.
In some embodiments, the modification is a modification to increase the melting temperature (Tm) between the blocking primer and the target nucleic. In some embodiments, the modification is a modification to decrease the melting temperature (Tm) between the blocking primer and the undesired nucleic acid which may be the wildtype nucleic acid in a method for selective enrichment of mutant nucleic acid in a sample. In some embodiments, wherein the modification is a modification to form an extra bridge connecting the 2′ oxygen and 4′ carbon of at least one nucleotide of the blocking primer, such as locked nucleic acid (LNA), see, e.g., Karkare S et al., Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 71(5):575-586, 2006 and VesterB et al., LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43(42):13233-13241, 2004.
In some embodiments, the reaction mixture comprises at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 400, 500, 600, 700, 800, 900 or 1000 different types of primer pairs. In some embodiments, the different types of pairs of the primers are complementary to different target nucleic acid fragments or are complementary to different sequences in the same target nucleic acid fragment.
The inventors of the present disclosure conducted a simulation experiment to evaluate the probability of forming primer pairs between primers with certain lengths generated randomly. The inventors randomly generated from 10 to 490 primer pairs in length of 20 bp to form different primer pools and, for each pool, checked primer dimer formation between any one primer and other primer in the same pool. It can be seen that the probability to form primer dimer (e.g., resulting from complementarily between different primers) is increased along with the increasing numbers of primers.
For the data in Table 1, 100% means that each primer in a primer pool forms a dimer with at least one of the other primers in the same primer pool and the length of the dimer is no shorter than the indicated number; 20% means that 20% of the primers in a primer pool forms dimers in the primer pool and the length of the dimer is no shorter than the indicated number.
For the data in Table 2, 100% means that each primer in a primer pool forms a dimer from its 3′ terminal with at least one of other primers in the same primer pool and the length of the dimer is no shorter than the indicated number, 10% means that 10% of the primers in a primer pool forms dimers in the primer pool and the length of the dimer is no shorter than the indicated number.
In some embodiments, there are no more than 20 complementary nucleotide pairings between any two primers. In some embodiments, there are no more than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 complementary nucleotide pairing between any two primers. In some embodiments, there are no more than 20 consecutive complementary nucleotide pairings between any two primers. In some embodiments, there are no more than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 consecutive complementary nucleotide pairings between any two primers. In some embodiments, the above mentioned complementary nucleotides pairings are within a region from the 1st nucleotide at the 3′ terminal of a primer to the 20th, 19th, 18th, 17th, 16th, 15th, 14th, 13th, 12th, 11th, 10th, 9th or 8th nucleotide from the 3′ terminal of the primer. In some embodiments, there are no more than 7, 6 or 5 consecutive complementary nucleotide pairings within a region from the 1st nucleotide at the 3′ terminal of a primer to the 20th, 19th, 18th, 17th, 16th, 15th, 14th, 13th, 12th, 11th, 10th, 9th or 8th nucleotide from the 3′ terminal of the primer. In some embodiments, when calculating the number of parings between two primers, the common tailing sequence is not counted.
In some embodiments, there are no more than 20 complementary nucleotide pairings and no more than 50% sequence complementarity between any two primers. In some embodiments, there are no more than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 complementary nucleotide pairings and no more than 45%, 40%, 35%, 30%, 25% or 20% sequence complementarity between any two primers. In some embodiments, when calculating the percent complementarity between two primers, the common tailing sequence is not counted.
The term “nucleotide complementarity” or “complementarity” when in reference to nucleotide as used in the present disclosure refers to a nucleotide on a nucleic acid chain is capable of base pairing with another nucleotide on another nucleic acid chain. For example, in DNA, adenine (A) is complementary to thymine (T), and guanine (G) is complementary to cytosine (C). For another example, in RNA, adenine (A) is complementary to uracil (U), and guanine (G) is complementary to cytosine (C).
The term “percent complementarity” as used in the present disclosure refers to the percentage of nucleotide residues in a nucleic acid molecule that have complementarity with nucleotide residues of another nucleic acid molecule when the two nucleic acid molecules are annealed. Percent complementarity is calculated by dividing the number of nucleotides of the first nucleic acid that are complementary to nucleotides at corresponding positions in the second nucleic acid by the total length of the first nucleic acid.
Percent complementarity of a nucleic acid or the number of nucleotides of a nucleic acid that is complementary to another nucleic acid can also be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 215, 403-410, 1990; Zhang and Madden, Genome Res., 7, 649-656, 1997).
For example, primer 1 in which 18 of 20 nucleotides of the primer 1 have complementarity with 18 nucleotides of primer 2 would have 90% sequence complementarity. In this example, the complementary nucleotides may be contiguous to each other or interspersed with non-complementary nucleotides.
The term “x nucleotide pairings” as used in the present disclosure refers to the number of nucleotide residues in a nucleic acid molecule that has complementarity with the corresponding nucleotides of another nucleic acid molecule when the two nucleic acid molecules are annealed. For example, “18 nucleotide pairings” means 18 nucleotide residues of a first nucleic acid molecule has complementarity with 18 nucleotide residues of a second nucleic acid molecule. In this example, the complementary nucleotides may be contiguous to each other or interspersed with non-complementary nucleotides.
Nucleic Acid Polymerase
In some embodiments, the nucleic acid polymerase may be selected from the family of DNA polymerases like E. coli DNA polymerase I (such as E. coli DNA polymerase I, Taq DNA polymerase, Tth DNA polymerase, TfI DNA polymerase and others). This polymerase may contain the naturally occurring wild-type sequences or modified variants and fragments thereof.
In some embodiments, the nucleic acid polymerase may be selected from modified DNA polymerases of the family of DNA polymerases like E. coli DNA polymerase I, e.g., N-terminal deletions of the DNA polymerases, such as Klenow fragment of E. coli DNA polymerase I, N-terminal deletions of Taq polymerase (including the Stoffel fragment of Taq DNA polymerase, Klentaq-235, and Klentaq-278) and others.
In some embodiments, the nucleic acid polymerase includes, but is not limited to, thermostable DNA polymerases. Examples of thermostable DNA polymerases include, but are not limited to: Tth DNA polymerase, TfI DNA polymerase, Taq DNA polymerase, N-terminal deletions of Taq polymerase (e.g., Stoffel fragment of DNA polymerase, Klentaq-235, and Klentaq-278). Other DNA polymerases include KlenTaqi, Taquenase™ (Amersham), Ad-vanTaq™ (Clontech), GoTaq, GoTaq Flexi (Promega), and KlenTaq-S DNA polymerase.
In some embodiments, the nucleic acid polymerase may be commercially available DNA polymerase mixtures, including but are not limited to, TaqLA, TthLA or Expand High Fidelitypius Enzyme Blend (Roche); TthXL Klen TaqLA (Perkin-Elmer); ExTaq® (Takara Shuzo); Elongase® (Life Technologies); Advantage™ KlenTaq, Advantage™ Tth and Advantage2™ (Clontech); TaqExtender™ (Stratagene); Expand™ Long Template and Expand™ High Fidelity (Boehringer Mannheim); and TripleMaster™ Enzyme Mix (Eppendorf).
For further decreasing the amplification of undesired nucleic acid, one or more additional polymerase can be added into the reaction mixture. In some embodiments, the reaction mixture comprises high fidelity polymerase. In some embodiments, the high fidelity polymerase is PFU DNA Polymerase, Klentaq-1, Vent, or Deep Vent.
De-Blocking Agent
De-blocking agent can be selected according to the blocking group contained in the blocking primer. De-blocking agent can be any agent that may result in de-blocking the block group in the blocking primer under the condition of amplifying the target nucleic acid, when the nucleotide with the blocking group in the blocking primer is complementary to the corresponding nucleotide in the target nucleic acid. In some embodiments, the de-blocking agent is pyrophosphate, CS5 DNA polymerase with the mutations selected from G46E, L329A, Q601R, D640G, I669F, S671F, E678G or the combination thereof. In some embodiments, the de-blocking agent is ampliTaq or KlenTaq polymerase with F667Y mutation, or RNase H2.
In some embodiments, the de-blocking agent is pyrophosphate, when the blocking group is 2′, 3′-dideoxynucleotide. In some embodiments, the de-blocking agent is CS5 DNA polymerase with the mutations selected from G46E, L329A, Q601R, D640G, I669F, S671F, E678G or the combination thereof (e.g., those DNA polymerases shown in U.S. 20070154914), when the blocking group is 2′-O—PO3 nucleotide. In some embodiments, the blocking group is 2′-O—PO3 nucleotide and the de-blocking agent is ampliTaq or KlenTaq polymerase with F667Y mutation, when the blocking group is 2′-O—PO3 nucleotide. In some embodiments, the de-blocking agent is RNase H2, when the blocking group is ribonucleotide residue.
Step of Incubating the Reaction Mixture Under a Condition for Amplification of the Target Nucleic Acid
Incubation of the reaction mixture of the present disclosure can be conducted in a multi-cycle process employing several alternating heating and cooling steps to amplify the DNA (see U.S. Pat. Nos. 4,683,202 and 4,683,195). In some embodiments, the incubation comprises the steps of denaturing the target nucleic acid; annealing the primers with the target nucleic acid to allow the formation of a target nucleic acid-primer hybrid; and incubating the target nucleic acid-primer hybrid to allow the nucleic acid polymerase to amplify the target nucleic acid.
An example of amplification process is briefly described below. First, a reaction mixture is heated to a temperature sufficient to denature the double stranded target DNA into its two single strands. The temperature of the reaction mixture is then decreased to allow specific single stranded primers to anneal to their respective complementary single-stranded target DNA. Following the annealing step, the temperature is maintained or adjusted to a temperature optimum of the DNA polymerase being used, which allows incorporation of complementary nucleotides at the 3′ ends of the annealed oligonucleotide primers thereby recreating double stranded target DNA. Using a heat-stable DNA polymerase, the cycle of denaturing, annealing and extension may be repeated as many times as necessary to generate a desired product, without the addition of polymerase after each heat denaturation (see “Current Protocols in Molecular Biology”, F. M. Ausubel et al., John Wiley and Sons, Inc., 1998).
In some embodiments, denaturing the target nucleic acid is conducted at about 90° C.-100° C. for from about 10 seconds to 10 minutes, preferably for the first circle for from about 1 to 8 minutes. In some embodiments, annealing the primers with the target nucleic acid is conducted at about 5° C.-60° C. for from about 3 seconds to 10 minutes. In some embodiments, incubating the nucleic acid-primer hybrid to allow the nucleic acid polymerase to amplify the target nucleic acid is conducted at about 60° C.-90° C. for from about 1 minute to 15 minutes.
In some embodiments, the incubation step is repeated at least 1 time, 5 times, 10 times, 15 times, 20 times, 25 times, 30 times, 35 times or 40 times. In some embodiments, the incubation step is repeated from about 20 times to about 50 times.
In some embodiments, the nucleic acid other than the target nucleic acid is not amplified in step (b) substantially. In some embodiments, the molar percentage of undesired nucleic acid in the product obtained after the incubation step is less than 20%, 15%, 10%, 5%, 3%, 2% or 1%.
The amplification method of the present disclosure can be used to construct DNA sequencing library. In some embodiments, the product obtained from the incubation step can be used as DNA sequencing library directly without enzyme digestion to reduce undesired amplification product. In some embodiments, the product obtained from the incubation step can be used as DNA sequencing library after the ligation of adaptor tags, but without enzyme digestion to reduce undesired amplification product.
“DNA sequencing library” as described in the present disclosure refers to a collection of DNA segments, in an abundance that can be sequenced, wherein one end or both ends of each segment in the collection of DNA segments contains a specific sequence partly or completely complementary to the primers used in sequencing, and thereby can be directly used in the subsequent DNA sequencing.
Some examples for construction of DNA sequencing library are shown in
In some embodiments, the method is used for selective enrichment of mutant nucleic acid in a sample comprising wildtype and mutant nucleic acid.
Some examples for selective enrichment of mutant nucleic acid are shown in
Another aspect of the present disclosure provides method of sequencing a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample, (ii) at least 20 different pairs of primers, wherein at least one primer of each primer pair is complementary to a portion of the target nucleic acid and comprises a blocking group capable of blocking polymerase extension (“blocking primer”), (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase; (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid; (c) determining the sequence of the products obtained from step (b).
The terms “sequencing” as used in the present disclosure refers to any and all biochemical methods that may be used to determine the identity and order of nucleotide bases including but not limited to adenine, guanine, cytosine and thymine, in one or more molecules of DNA. In some embodiments, the method is use for sequencing by capillary electrophoresis, PCR or high throughput sequencing (e.g., next-generation sequencing (NGS)).
Yet another aspect of the present disclosure provides a method of sequencing a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample, (ii) at least 20 different pairs of primers, wherein at least one primer of each primer pairs is complementary to a portion of the target nucleic acid and comprises a blocking group capable of blocking polymerase extension (“blocking primer”), (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase; (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid; (c) adding adaptor tag, molecular index tag and/or sample index tag to the product obtained from step (b); (d) determining the sequence of the products obtained from step (c).
In some embodiments, in the step (c), adaptor tag, molecular index tag and/or sample index tag is attached to the target nucleic acid obtained from step (b). The adaptor tag, molecular index tag and/or sample index tag can be attached according to the method mentioned above.
Yet another aspect of the present disclosure provides a kit of amplifying a target nucleic acid, wherein the kit comprises: (i) at least 20 different pairs of primers, wherein at least one primer of each primer pairs is complementary to a portion of the target nucleic acid and comprises a blocking group capable of blocking polymerase extension, (ii) nucleic acid polymerase, and (iii) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase.
In some embodiments, the kit further comprises one or more agents selected from dNTPs, Mg2+ (e.g., MgCl2), Bovin Serum Albumin, pH buffer (e.g., Tris HCL), glycerol, DNase inhibitor, RNase, SO42−, Cl−, K+, Ca2+, Na+, and (NH4)+.
In some embodiments, the kit further comprises an instruction showing how to conduct the amplification of the target nucleic acid (such as showing those methods of the present disclosure).
Yet another aspect of the present disclosure provides a method of amplifying a target nucleic acid, wherein the method comprises: (a) providing a reaction mixture comprising: (i) a nucleic acid sample, (ii) at least one primer that is complementary to a portion of the target nucleic acid and comprises a blocking group capable of blocking polymerase extension (“blocking primer”), wherein the blocking primer is modified so as to decrease the amplification of undesired nucleic acid, (iii) nucleic acid polymerase, and (iv) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase; (b) incubating the reaction mixture under a condition for amplification of the target nucleic acid.
Yet another aspect of the present disclosure provides a kit of amplifying a target nucleic acid, wherein the kit comprises: (i) at least one primer that is complementary to a portion of the target nucleic acid and comprises a blocking group capable of blocking polymerase extension (“blocking primer”), wherein the blocking primer is modified so as to decrease the amplification of undesired nucleic acid, (ii) nucleic acid polymerase, and (iii) de-blocking agent capable of enabling polymerization of the target nucleic acid by said nucleic acid polymerase.
Any embodiment following any aspect of the present disclosure can be applied to other aspects of the present disclosure, as long as the resulted embodiments are possible or reasonable for a person skilled in the art.
It is understood that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to a “bridge probe” is a reference to one or more bridge probes, and includes equivalents thereof known to those skilled in the art and so forth.
All publications and patents cited in this specification are herein incorporated by reference to their entirety.
The invention will be more readily understood with reference to the following examples, which are not to be interpreted in any way as limiting the scope of the invention. All specific compositions, materials, and methods described below, in whole or in part, fall within the scope of the invention. These specific compositions, materials, and methods are not intended to limit the invention, but merely to illustrate specific embodiments falling within the scope of the invention. One skilled in the art may develop equivalent compositions, materials, and methods without the exercise of inventive capacity and without departing from the scope of the invention. It will be understood that many variations can be made in the procedures herein described while still remaining within the bounds of the invention. It is the intention of the inventors that such variations are included within the scope of the invention.
A multiplex polymerase chain reaction was performed to selectively amplify 196 amplicons (the products amplified from target nucleic acid regions) across human genomic DNA. Each primer pair contains two primers with dideoxynucleoside terminated at its 3′ end and can selectively hybridize target nucleic acid. The sequence of each primer pair is shown in Table 3. The boldfaced sequences in each primer are the sequences for the following step of the library construction and other sequences in each primer are the sequences for selectively hybridizing target nucleic acid.
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAA
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCBG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGA
TCTTCCGATCTAT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTYTG
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGGT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCT
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGC
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCR
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTgCC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAT
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCC
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCA
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGG
TCTTCCGATCTTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAA
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCA
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAT
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACC
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGC
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCT
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCATC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGC
TCTTCCGATCTGT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTTC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCA
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCCT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCC
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCA
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACR
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
T
CTTCCGATCTCC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCYC
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGA
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGA
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTC
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCAT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCA
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTATT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGC
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTC
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAT
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGGG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTAC
TCTTCCGATCTGT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACTT
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGGC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTG
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAG
TCTTCCGATCTGT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAATT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTT
TCTTCCGATCTGT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTA
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATG
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGT
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGG
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTT
TCTTCCGATCTAT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGGG
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTC
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCATC
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTSCC
TCTTCCGATCTAT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTG
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATTA
TCTTCCGATCTTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACT
TCTTCCGATCTTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCC
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAC
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTACT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTTC
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATCT
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCGC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGCT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGAG
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCTT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATA
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCATC
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTCT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATA
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAC
TCTTCCGATCTCT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCA
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCCT
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTATAC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTA
TCTTCCGATCTAT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGTT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTACC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTG
TCTTCCGATCTTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTACT
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCA
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGC
TCTTCCGATCTT
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTGAT
TCTTCCGATCTCA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTTC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGC
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCC
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAAG
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTAGA
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCTTT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTCTT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTACA
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAC
TCTTCCGATCTG
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTCAT
TCTTCCGATCTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTGGT
TCTTCCGATCTA
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTAG
TCTTCCGATCTTC
ACACTCTTTCCC
GTGACTGGAGT
TACACGACGCTC
TCAGACGTGTGC
TTCCGATCTTTCT
TCTTCCGATCTT
Amplification of the target nucleic acid regions. A pool of 196 amplicon primer pairs in a concentration of 50 nM for each primer were added to a single PCR tube, 50 ng of human genomic DNA (GenBank No.: NA12878) and 10 μL of amplification reaction mixture which contains 3% glycerol, 0.2 nM dNTPs, 50 nM pyrophosphate and 2 units of KlenTaq-S DNA polymerase to a final volume of 20 μL with DNase/RNase free water. The PCR tube was put on a thermal cycler and run the following temperature profile to get the amplified amplicon library. An initial holding stage was carried out at 98° C. for 2 minutes, followed by 98° C. 15 seconds, 55° C. 8 minutes, for 17 cycles. After cycling, the reaction was held at 72° C. for 5 minutes and then 4° C. until proceeding to the beads purification step to remove excess primers. The tube cap was carefully removed and 24 μL of Agencourt AMPure® XP Reagent (Beckman Coulter, CA) was added to the reaction mixture to purify the DNA. The reaction mixture was vortex mixed and incubated for 5 minutes at room temperature. The tube was placed in a magnetic rack and incubated until solution clears. The supernatant was carefully remove and discarded without disturbing the pellet, then 150 μL of freshly prepared 70% ethanol was added. The reaction mixture was vortexed to mix well, pulsed spin, and incubated until solution clears. The supernatant was carefully removed and discarded without disturbing the pellet. Another portion of 150 μL of freshly prepared 70% ethanol was added. The reaction mixture was vortexed to mix well, pulsed spin, and incubated until solution clears. The supernatant was carefully removed and discarded without disturbing the pellet. Leave the tube open to evaporate for about 2 minutes. The remaining bead pellet in the tube contains the purified DNA.
Construction of library. Then 50 μL of Platinum® PCR SuperMix High Fidelity DNA Polymerase (Thermo Fisher, Cat #12532016) and 2 μL of Library Amplification Barcoded Primer Mix (10 μM concentration for each primer was added to bead pellet). The sequence of each primer is shown in Table 4. The PCR tube was put on a thermal cycler and run the following temperature profile to get the amplified amplicon library. An initial holding stage was carried out at 98° C. for 2 minutes, followed by 98° C. 15 seconds, 60° C. 1 minute, for 5 cycles. After cycling, the reaction was held at 72° C. for 5 minutes and then kept at 4° C. until purification. The tube cap was carefully removed and 44 μL of Agencourt AMPure® XP Reagent (Beckman Coulter, CA) was added to the reaction mix for purifying the product. The reaction was vortex mixed and incubated for 5 minutes at room temperature. The tube was placed in a magnetic rack and incubated until solution clears. The supernatant was carefully removed and discarded without disturbing the pellet. Then 150 μL of freshly prepared 70% ethanol was added to the pellet; the reaction mixture was vortexed to mix well, pulsed spin, and incubated until solution clears; the supernatant was carefully removed and discarded without disturbing the pellet; the foregoing wash step was repeated for another time. After the wash, leave the tube open to evaporate for about 2 minutes. Then 50 μL of low TE buffer was added and the solution was vortexed thoroughly. The tube was placed in the magnet until solution clears. The supernatant containing library was collected to a separate clean tube. The library was quantified using Qubit® 2.0 Fluorometer (Life Technologies, CA) and Bioanalyzer (Agilent Technologies, CA) according to manufacturer protocol.
The library was sequenced on Illumina MiSeq sequencer according to manufacturer's procedure.
Data Processing
Sequencing reads were aligned to GRC37/hg19 reference genome downloaded from web of ucsc genome browser (hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/) using the software of bowtie2 (downloaded from sourceforge.net/projects/bowtie-bio/files/bowtie/1.2.1.1) with default settings. The aligned reads were further assigned to amplicons based on the match between positions of reads of R1 and R2 in genome and positions of forward and reverse primers of designed assays. The preliminary results indicated that performances of cancer hot spot panel were (1) 69.7% reads aligned to genome; (2) 95.5% reads aligned to target regions of design; (3) 98.1% of assays with amplicon read coverage within 5-fold of the mean average.
In 20 μL PCR reaction solution, two pools of 8 primer pairs (see Table 5) with each primer containing dideoxynucleotide at its 3′ end in 0.5 μM concentration were added together with 2 μL of 10×PCR buffer, 3 mM MgCl2, 0.2 mM dNTP, 50 nM pyrophosphate, 2 units of AmpliTaq DNA polymerase FS and 1%, 0.1% or 0.01% mutant nucleic acid (Horizon discovery, Cambridge, United Kingdomin), 30 ng of human genomic DNA (GenBank No.: NA12878). The PCR tube was loaded on a thermal cycler and run the following temperature profile: 95° C. for 2 min; 95° C. 15 seconds, 65° C. 120 seconds, for 40 cycles; hold at 4° C. 5 μL ExoSAP-IT™ solution (Affymetrix, CA) was added to the tube, and the reaction was incubated at 37° C. for 15 min, 80° C. for 10 min, held at 4° C. 2 μL of reaction solution was used to perform cycle sequencing with BigDye™ Terminator v3.1 cycle sequencing kit (Life Technologies, CA) and the resulting DNA was purified according to manufacturer protocol. The purified sample electrophoresis was carried out on ABI Prism 3730 DNA analyzer according to manufacturer recommended protocol. Electropherogram in
In 20 μL PCR reaction solution, a pair of primers (one primer is SMDCR0166 and the other primer is selected from one of SMDMF0166, SMDMF0166G3, SMDMF0166G6, SMDMF0166C9, SMDMF0166C12, SMDMF0166G15) (see Table 6) with each primer containing dideoxynucleotide at its 3′ end in 0.5 μM concentration were added with 2 μL of 10×PCR buffer, with final concentration of 3 mM MgCl2, 0.2 mM dNTP, 90 μM of pyrophosphate and 2 units of KlenTaq-S. 30 ng of 100% wild type human genomic DNA (see Table 6) or wild type human genomic DNA spiked with 0.1% mutant genomic DNA (EGFR T790M, see Table 6) was also added to the PCR reaction mixture. The PCR tube was loaded on a thermal cycler and run the following temperature profile: 95° C. for 2 min; 95° C. 15 seconds, 65° C. 120 seconds, for 40 cycles; held at 4° C. 5 μL ExoSAP-IT™ solution (Affymetrix, CA) was added to the tube, and the reaction was incubated at 37° C. for 15 min, 80° C. for 10 min, held at 4° C. 2 μL of treated reaction solution was used to perform cycle sequencing reaction with BigDye™ Terminator v3.1 cycle sequencing kit (Life Technologies, CA) and purified according to manufacturer protocol. The purified sample electrophoresis was carried out on ABI Prism 3730 DNA analyzer according to manufacturer recommended protocol. The results are shown in
In 20 μL PCR reaction solution, forward and reverse primer pairs (see Table 7) with each primer containing dideoxynucleotide at its 3′ end in 0.5 μM concentration were added with 2 μL of 10×PCR buffer, with final concentration of 3 mM MgCl2, 0.2 mM dNTP, 90 μM of pyrophosphate and 2 units of KlenTaq-S with or without 2 units of Pfu DNA polymerase (Promega, Wis.) were added to the reaction mixture. Then 30 ng of 100% wild type human genomic DNA (NA12878) (see Table 7) or wild type human genomic DNA (NA12878) spiked with 0.10% mutant genomic DNA (EGFR G719S, see Table 7) was also added to the PCR reaction mixture. The PCR tube was loaded on a thermal cycler and run the following temperature profile: 95° C. for 2 min; 95° C. 15 seconds, 65° C. 120 seconds, for 40 cycles, held at V° C. 5 μL ExoSAP-IT™ solution (Affymetrix, CA) was added to the tube, and the reaction was incubated at 37° C. for 15 min, 80° C. for 10 min, held at 4° C. 2 μL of treated reaction solution was used to perform cycle sequencing with BigDye™ Terminator v3.1 cycle sequencing kit (Life Technologies, CA) and purified according to manufacturer protocol. The purified sample electrophoresis was carried out on ABI Prism 3730 DNA analyzer according to manufacturer recommended protocol. The results are shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/CN2017/103393 | Sep 2017 | WO | international |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2018/106436 | 9/19/2018 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2019/062614 | 4/4/2019 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 6534269 | Liu et al. | Mar 2003 | B2 |
| 7238480 | Liu et al. | Jul 2007 | B2 |
| 20040175733 | Andersen | Sep 2004 | A1 |
| 20140329245 | Spier | Nov 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 103266103 | Aug 2013 | CN |
| 105368924 | Mar 2016 | CN |
| 106811537 | Jun 2017 | CN |
| 106987622 | Jul 2017 | CN |
| 2015073931 | May 2015 | WO |
| Entry |
|---|
| International Search Report of PCT Application No. PCT/CN2018/106436, dated Dec. 26, 2018. |
| Ku, C.-S. et al., “A new era in the discovery of de novo mutations underlying human genetic disease”, Human Genomics (2012), vol. 6, p. 27. |
| Chiu, R. W. K. et al., “Noninvasive prenatal diagnosis empowered by high-throughput sequencing”, Prenatal Diagnosis (2012), vol. 32, pp. 401-406. |
| Helleday, T. et al., “Mechanisms underlying mutational signatures in human cancers”, Nature Reviews Genetics (Sep. 2014), vol. 15(9), pp. 585-598. doi:10.1038/nrg3729. |
| Veltman, J. A. et al., “De novo mutations in human genetic disease”, Nature Reviews Genetics (Aug. 2012), vol. 13, pp. 565-575. |
| Number | Date | Country | |
|---|---|---|---|
| 20210189477 A1 | Jun 2021 | US |
